Form 144 BELITE BIO, INC Filed by: Liaw Wei-Cheng
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt DiseaseGlobeNewswire
- Belite Bio to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- Belite Bio names Hendrik P. N. Scholl as chief medical officer [Seeking Alpha]Seeking Alpha
BLTE
Earnings
- 8/9/24 - Miss
BLTE
Sec Filings
- 9/4/24 - Form 144
- 9/3/24 - Form 6-K
- 8/16/24 - Form 144
- BLTE's page on the SEC website